Law Seminars International: Pharmaceutical Antitrust: Practical Insights on Navigating Government Litigations and Private Litigation

Law Seminars International: Pharmaceutical Antitrust: Practical Insights on Navigating Government Litigations and Private Litigation

Speaking Engagement

Law Seminars International has assembled leading government enforcers and policy makers from the Federal Trade Commission and Congress to provide an on-the-ground assessment of the new Washington challenges for pharmaceutical companies. Prominent in-house and outside counsel as well as industry executives will offer guidance on current competition issues facing the pharmaceutical industry and practical ways to handle key business decisions with potential antitrust hazards.

Attendees will learn how to determine antitrust exposure in the current legal and regulatory environment, how to identify and form pro-competitive mergers and joint ventures and how to approach a variety of transactions in order to maximize your products’ values without triggering expensive and time-consuming government actions or litigation. Additionally, this conference will provide practical insight on navigating government investigations and private litigation.

WilmerHale partner, Jim Burling, will speak on a panel entitled, "Maximizing the Life-Cycle of Products". This session will discuss lessons from recent cases: identifying antitrust risks, strategies for patent acquisition, Orange Book de-listing and end-of-life management; citizen petitions; authorized generics; aggressive patent strategies while minimizing antitrust risks.

Read More About the Event

Speakers

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.